MedTrace Logo

A Study of LX107 Gene Therapy in AIPL1-IRD Patients

NCT07063030 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-03-10

No results posted yet for this study

Summary

Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.

Conditions

  • Retinal Dystrophy

Interventions

GENETIC

LX107 Injection

Subjects will receive subretinal injection of LX107 on Day 0.

Sponsors & Collaborators

  • Innostellar Biotherapeutics Co.,Ltd

    collaborator INDUSTRY

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07063030 on ClinicalTrials.gov